following an abbreviated submission:
bimekizumab (Bimzelx®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.
Bimekizumab provides an additional treatment choice in the therapeutic class of interleukin inhibitors.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice630KB (PDF)
Medicine details
- Medicine name:
- bimekizumab (Bimzelx)
- SMC ID:
- SMC2410
- Indication:
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Skin
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 08 November 2021